EWM
PRME icon

Endurance Wealth Management’s Prime Medicine PRME Stock Holding History

Endurance Wealth Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$8K Hold
500
– – ﹤0.01% 518
2023
Q1 		$0 Buy
+500
New +$8.14K ﹤0.01% 657

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Endurance Wealth Management's PRME Position: Q2 2023 in Review

Endurance Wealth Management held its Prime Medicine (PRME) position steady in Q2 2023 at 500 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #518.

Endurance Wealth Management first reported a position in PRME in Q1 2023 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold PRME as of Q2 2023.

  • Endurance Wealth Management held 500 shares of Prime Medicine worth $8K as of Q2 2023.
  • Endurance Wealth Management left its Prime Medicine share count unchanged in Q2 2023.
  • Prime Medicine made up ﹤0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #518 holding.
  • Endurance Wealth Management first reported a position in Prime Medicine in Q1 2023 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.